Teva Keeps Win Over Corcept Korlym Patent Lawsuit on Appeal (1)

Teva Pharmaceutical Industries Ltd.‘s generic version of Corcept Therapeutics Inc.'s Korlym doesn’t infringe two patents on dosing methods for treating Cushing’s syndrome, a federal appeals court ruled.

A three-judge panel at the US Court of Appeals for the Federal Circuit found no clear error in a New Jersey district judge’s conclusion that Corcept failed to prove doctors would actually perform the methods covered by US Patent Nos. 10,842,800 and 10,195,214 if Teva’s copy reaches the market, even though the proposed label mirrors Korlym’s current instructions, according to an opinion issued Thursday.

District Judge Renee Marie Bumb’s December 2023 ruling ...